Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
Pseudomyxoma peritonei is characterized by disseminated intra-peritoneal mucinous tumors and mucinous ascites in the abdomen and pelvis.
Biomarker and diagnostic research for pseudomyxoma peritonei has been reported in the published literature.
No approved treatments are currently available for pseudomyxoma peritonei. An additional 1 compound holds orphan drug designation.
While no drugs are FDA-approved specifically for pseudomyxoma peritonei, some of the following designated compounds may be used off-label in clinical practice. Treatment decisions should be made in consultation with a specialist familiar with this condition.
The following drugs have received orphan drug designation from the FDA for pseudomyxoma peritonei. Orphan designation reflects regulatory interest and does not indicate approval for treatment.
Brand Name | Generic Name | Sponsor |
|---|
Estimated prevalence: Unknown (Unknown prevalence).
13 clinical trials registered, 9 recruiting. Interventions under study include drug therapy, other interventions, procedural interventions, and biologic therapy. Pipeline includes 1 PHASE3, 5 PHASE2, 1 EARLY_PHASE1. Research is primarily sponsored by academic and government institutions.
NCT ID | Title | Phase | Sponsor | Status |
|---|---|---|---|---|
[NCT04024917](https://clinicaltrials.gov/study/NCT04024917) |
Data assembled from 5 of 12 sources · Last updated Sep 19, 2026, 7:47 AM UTC
European rare disease database
Genetic and Rare Diseases Info Center
Designated
Exclusivity End |
|---|
Designation Status |
|---|
bromelain + acetylcysteine | bromelain + acetylcysteine | MUCPharm Pty Ltd. | 2018 | — | Designated |
Gene therapy approaches for pseudomyxoma peritonei have been reported in the published literature.
13 trials found
Impact of Cardiac Coherence on Anxiety in Patients Operated on for a Peritoneal Carcinosis |
NA |
Institut du Cancer de Montpellier - Val d'Aurelle |
RECRUITING |
[NCT07328737](https://clinicaltrials.gov/study/NCT07328737) | One vs Three HIPEC Cycles After CRS for Pseudomyxoma Peritonei | NA | Beijing Tsinghua Chang Gung Hospital | RECRUITING |
[NCT06800391](https://clinicaltrials.gov/study/NCT06800391) | Metronomic Neoadjuvant Capecitabine and Cyclophosphamide in HUGE Pseudomyxoma Peritonei Patients | PHASE2 | Fondazione IRCCS Istituto Nazionale dei Tumori, Milano | RECRUITING |
[NCT01617382](https://clinicaltrials.gov/study/NCT01617382) | Register With Patients in Which Hyperthermic Intra-Peritoneal Chemotherapy (HIPEC) Was Performed | — | Universitaire Ziekenhuizen KU Leuven | RECRUITING |
[NCT02073500](https://clinicaltrials.gov/study/NCT02073500) | Peritoneal Surface Malignancies - Characterization, Models and Treatment Strategies | — | Oslo University Hospital | RECRUITING |
210 publications have been identified in PubMed for pseudomyxoma peritonei. Research spans Review / Meta-Analysis (27%), Case Report / Case Series (26%), and Clinical Trial Publication (15%).
Research Type | Count | % of Total |
|---|---|---|
Research summaries | 47 | 27% |
Patient case studies | 45 | 26% |
Clinical study results | 26 | 15% |
Disease patterns and progression | 18 | 10% |
Testing and diagnosis research | 15 | 9% |
Laboratory research | 12 | 7% |
Other research | 5 | 3% |
New treatment approaches | 4 | 2% |
Aulicino M (2026). [PMID: 42104034](https://pubmed.ncbi.nlm.nih.gov/42104034/). *Ann Surg Oncol*. [Basic Science / Preclinical]
Leal-Hidalgo JL (2026). [PMID: 41804302](https://pubmed.ncbi.nlm.nih.gov/41804302/). *Cureus*. [Clinical Trial Publication]
Feng S (2026). [PMID: 42255252](https://pubmed.ncbi.nlm.nih.gov/42255252/). *Front Oncol*. [Case Report / Case Series]
Zhao QD (2026). [PMID: 41947779](https://pubmed.ncbi.nlm.nih.gov/41947779/). *Medicinal research reviews*. [Review / Meta-Analysis]
Chen QH (2026). [PMID: 41175480](https://pubmed.ncbi.nlm.nih.gov/41175480/). *Eur J Surg Oncol*. [Review / Meta-Analysis]
Sticca G (2026). [PMID: 41037221](https://pubmed.ncbi.nlm.nih.gov/41037221/). *Ann Surg Oncol*. [Clinical Trial Publication]
Torgunrud A (2026). [PMID: 41868810](https://pubmed.ncbi.nlm.nih.gov/41868810/). *Pleura Peritoneum*. [Epidemiology / Natural History]
D'Annibale G (2026). [PMID: 42150629](https://pubmed.ncbi.nlm.nih.gov/42150629/). *J Gastrointest Surg*. [Diagnostic / Biomarker]
Gao S (2026). [PMID: 41694806](https://pubmed.ncbi.nlm.nih.gov/41694806/). *Front Surg*. [Epidemiology / Natural History]
Rintala JM (2026). [PMID: 41351458](https://pubmed.ncbi.nlm.nih.gov/41351458/). *Scand J Surg*. [Epidemiology / Natural History]
AI-curated news mentioning pseudomyxoma peritonei
Updated Jun 5, 2026
Recent research highlights the relationship between the microbiome and pseudomyxoma peritonei, revealing emerging observations and unanswered questions. This study may pave the way for future investigations into the role of microbiota in this rare disease.
A recent study identifies risk factors for pseudomyxoma peritonei in patients with appendiceal mucinous neoplasms. This single-center experience provides insights that could inform future research and clinical management.